Skip to content
Screener

Eikon Therapeutics, Inc. EIKN Restricted Cash

Restricted Cash at other companies

IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$1.28M+59.1%
Immunome logo
ImmunomeIMNM
$210K0.0%
Erasca, Inc. logo
Erasca, Inc.ERAS
$408K0.0%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$3M0.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$1.28M+164%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$316K-0.6%

Other financials

Income statement

See full
Operating income-$87.3M-22.3%
Net income-$83.0M-21.6%
EPS (diluted)-$2.46+90.9%

Balance sheet

See full
Cash & equivalents$161.2M-21.2%
Total debt$254.8M—
Total equity$550.7M+186%
Total assets$850.8M—

Cash flow

See full
Operating cash flow-$89.8M-64.7%
CapEx$262.0K-98.8%
Free cash flow-$90.1M-17.1%

Valuation

See full
Market cap$526.77M-32.7%
Enterprise value$620.45M—

Returns & leverage

See full
Debt / equity0.5×—
Current ratio11.8×—

Where this comes from

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.

The source filing: Eikon Therapeutics, Inc.’s 10-Q, filed May 11, 2026. Open the filing →

Filed
May 11, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-216791

FAQ

What is Eikon Therapeutics, Inc.'s restricted cash?
Eikon Therapeutics, Inc. (EIKN) reported restricted cash of $400K in Q1 2026.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.

Ask your AI about Eikon Therapeutics, Inc.'s restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude